INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 133 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2018. The put-call ratio across all filers is 0.53 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $329,711 | -18.3% | 4,814 | -17.5% | 0.16% | -24.8% |
Q1 2024 | $403,644 | +12.9% | 5,833 | +16.8% | 0.21% | -5.7% |
Q4 2023 | $357,670 | +45.4% | 4,994 | +5.7% | 0.23% | +52.3% |
Q3 2023 | $246,021 | -27.2% | 4,723 | -11.5% | 0.15% | -25.5% |
Q2 2023 | $337,876 | +6.8% | 5,336 | -8.6% | 0.20% | +14.9% |
Q1 2023 | $316,236 | +4.2% | 5,840 | +1.9% | 0.17% | +10.1% |
Q4 2022 | $303,390 | +49.5% | 5,733 | +31.6% | 0.16% | +95.1% |
Q3 2022 | $203,000 | -17.1% | 4,357 | +1.4% | 0.08% | -11.0% |
Q2 2022 | $245,000 | -61.6% | 4,296 | -58.8% | 0.09% | -68.2% |
Q1 2022 | $638,000 | +17.1% | 10,419 | 0.0% | 0.29% | +38.8% |
Q4 2021 | $545,000 | +36.6% | 10,419 | -2.7% | 0.21% | +17.0% |
Q3 2021 | $399,000 | -16.4% | 10,703 | -8.4% | 0.18% | -10.2% |
Q2 2021 | $477,000 | -43.2% | 11,679 | -52.8% | 0.20% | -44.8% |
Q1 2021 | $840,000 | +9.7% | 24,764 | +2.8% | 0.36% | +11.6% |
Q4 2020 | $766,000 | +94.9% | 24,085 | +57.4% | 0.32% | +54.4% |
Q3 2020 | $393,000 | -11.9% | 15,303 | -12.0% | 0.21% | -2.4% |
Q2 2020 | $446,000 | +3.5% | 17,392 | -38.0% | 0.21% | +19.2% |
Q1 2020 | $431,000 | -60.9% | 28,050 | -12.7% | 0.18% | -1.7% |
Q4 2019 | $1,103,000 | +630.5% | 32,139 | +59.1% | 0.18% | +500.0% |
Q3 2019 | $151,000 | -45.5% | 20,197 | -5.3% | 0.03% | -48.3% |
Q2 2019 | $277,000 | +20.4% | 21,322 | +12.9% | 0.06% | -88.1% |
Q1 2019 | $230,000 | -6.5% | 18,878 | -12.7% | 0.49% | +1064.3% |
Q4 2018 | $246,000 | -49.1% | 21,613 | -2.9% | 0.04% | -16.0% |
Q3 2018 | $483,000 | -28.4% | 22,258 | -41.7% | 0.05% | -91.6% |
Q2 2018 | $675,000 | -36.0% | 38,174 | -23.8% | 0.60% | -34.8% |
Q1 2018 | $1,054,000 | +214.6% | 50,088 | +116.8% | 0.92% | +117.9% |
Q4 2017 | $335,000 | -30.6% | 23,102 | -24.5% | 0.42% | +546.2% |
Q3 2017 | $483,000 | +40.0% | 30,600 | +10.1% | 0.06% | +27.5% |
Q2 2017 | $345,000 | +15.8% | 27,801 | +51.7% | 0.05% | -3.8% |
Q1 2017 | $298,000 | +19.2% | 18,329 | +10.6% | 0.05% | -29.3% |
Q4 2016 | $250,000 | +155.1% | 16,572 | +157.2% | 0.08% | +59.6% |
Q3 2016 | $98,000 | -60.8% | 6,443 | 0.0% | 0.05% | -74.7% |
Q2 2016 | $250,000 | – | 6,443 | – | 0.19% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DCF Advisers, LLC | 375,000 | $15,308,000 | 5.42% |
SILVERARC CAPITAL MANAGEMENT, LLC | 113,258 | $4,623,000 | 2.06% |
Tri Locum Partners LP | 150,783 | $6,155,000 | 2.02% |
COOPER/HAIMS ADVISORS, LLC | 61,116 | $2,495,000 | 1.64% |
Vantage Consulting Group Inc | 226,670 | $9,252,000 | 1.61% |
Nicholas Investment Partners, LP | 598,261 | $24,421,000 | 1.53% |
Bellevue Group AG | 3,609,919 | $147,357,000 | 1.44% |
GENERAL AMERICAN INVESTORS CO INC | 350,804 | $14,320,000 | 1.20% |
Rhenman & Partners Asset Management AB | 429,728 | $17,541,000 | 1.19% |
WASATCH ADVISORS LP | 6,506,789 | $265,607,000 | 1.08% |